Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 608-614

  Janovick, Jo Ann ^a   Goulet, Mark ^b   Bush, Eugene ^c   Greer, Jonathan ^c   Wettlaufer, David G ^d   Conn, P Michael ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ABBOTT LABORATORIES   (United States)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 DEOXY 11 (CARBOXYPHENYLETHYLAMINO) 6 O METHYL ERYTHROMYCIN A 11,12 CYCLIC CARBAMATE; 2 [2 [[7 CHLORO 6 [(6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)CARBONYL] 3 (3,5 DIMETHYLPHENYL) 2 OXO 1,2 DIHYDROQUINOLIN 4 YL]OXY]ETHYL]PIPERIDINIUM TRIFLUOROACETATE; 2 [5 [2 (2 AZABICYCLO[2.2.2]OCT 2 YL) 1,1 DIMETHYL 2 OXOETHYL] 2 (3,5 DIMETHYLPHENYL) 1H INDOL 3 YL] N (2 PYRIDIN 4 YLETHYL)PROPAN 1 AMINE; 2 [5 [2 (2 AZABICYCLO[2.2.2]OCT 2 YL) 1,1 DIMETHYL 2 OXOETHYL] 2 (3,5 DIMETHYLPHENYL) 1H INDOL 3 YL] N [2 [4 (METHYLSULFINYL)PHENYL]ETHYL]PROPAN 1 AMINE; 3' N NOR 3' N CYCLOPENTYL 11 DEOXY 11 [CARBOXY (3,4 DICHLOROPHENYLETHYLAMINO)] 6 O METHYL ERYTHROMYCIN A 11,12 CYCLIC CARBAMATE; 3',3' N CYCLOPROPYLMETHYL 11 DEOXY 11 [CARBOXY (3 CHLORO 4 FLUOROPHENYLETHYLAMINO)] 6 O METHYL ERYTHROMYCIN A 11,12 CYCLIC CARBAMATE; 7 CHLORO 2 OXO 4 [2 (PIPERIDIN 2 YL)ETHOXY] N PYRIMIDIN 4 YL 3 (3,4,5 TRIMETHYLPHENYL) 1,2 DIHYDROQUINOLINE 6 CARBOXAMIDE; A 177775; A 222509; A 64755; A 7662; CHAPERONE; CYSTEINE; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; IN 3; IN 30; IN 31 B; INDOLE DERIVATIVE; MACROLIDE; MUTANT PROTEIN; N [2 (4 CARBOXYPHENYL)ETHYL] 2 [5 [1,1 DIMETHYL 2 (4 METHYLPIPERAZIN 1 YL) 2 OXOETHYL] 2 (3,5 DIMETHYLPHENYL) 1H INDOL 3 YL]PROPAN 1 AMINIUM TRIFLUOROACETATE; N [7 CHLORO 3 (3,5 DIMETHYLPHENYL) 2 OXO 4 [2 (PIPERIDIN 2 YL)ETHOXY] 1,2 DIHYDROQUINOLIN 6 YL] N' CYCLOPROPYLUREA; Q 08; Q 76; Q 89; QUINOLONE DERIVATIVE; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DELETION MUTANT; DRUG EFFICACY; DRUG STRUCTURE; HYPOGONADOTROPIC HYPOGONADISM; MATERIALS; MEASUREMENT; MEMBRANE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BINDING SITES; BUSERELIN; CERCOPITHECUS AETHIOPS; COS CELLS; GENETIC VECTORS; HUMANS; INDOLES; LIGANDS; MACROLIDES; MOLECULAR CHAPERONES; MUTATION; QUINOLONES; RATS; RECEPTORS, LHRH; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0344059035     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.048454     Document Type: Article

References (32)

1. Achermann JC and Jameson IL (2001) Advances in molecular genetics of hypogonadotropic hypogonadism. J Pediatr Endocrinol Metab 14:3-15.
2. Arora KK, Chung HO, and Catt KJ (1999) Influence of a species-specific extracellular amino acid on expression and function of the human gonadotropin-releasing hormone receptor. Mol Endocrinol 13:890-896.
3. Ashton WT, Sisco RM, Kieczykowski GR, Yang YT, Yudkovitz JB, Cui J, Mount GR, Ren RN, Wu T, Shen X, et al. (2001a) Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. Bioorg Med Chem Lett 11:2597-2602.
4. Ashton WT, Sisco RM, Yang YT, Lo JL, Yudkovitz JB, Cheng K, and Goulet MT (2001b) Potent nonpeptide GnRH receptor antagonists derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side-chain terminus. Bioorg Med Chem Lett 11:1727-1731.
5. Ashton WT, Sisco RM, Yang YT, Lo JL, Yudkovitz JB, Cheng T, and Goulet MT (2001c) Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists. Bioorg Med Chem Lett 11:1723-1726.
6. Bellotti V, Mangione P, and Stoppini M (1999) Biological activity and pathological implications of misfolded proteins. Cell Mol Life Sci 55:977-991.
7. Brooks DA (1999) Introduction: molecular chaperones of the ER: their role in protein folding and genetic disease. Semin Cell Dev Biol 10:441-442.
8. Brothers S, Janovick JA, Maya-Núñez G, Cornea A, Han X, and Conn PM (2002) Conserved mammalian gonadotropin-releasing hormone receptor carboxyl terminal amino acids regulate ligand binding, effector coupling and internalization. Mol Cell Endocrinol 190:19-27.
9. Bush EN, Kramer DL, Cybulski VA, Mohning KM, Besecke LM, Diaz GJ, Bammert GF, Sauer D, Haviv F, Borre A, et al. (1999) Activity and pharmacokinetics of A-177775, a non-peptide GnRH antagonist, in rats and dogs, in Program and Abstracts of the 81st Annual Meeting of the Endocrine Society, San Diego, CA, Abstract P3-225.
10. Conn PM, Leaños-Miranda A, and Janovick J (2002) Protein Origami: therapeutic rescue of misfolded gene products. Mol Interven 2:308-316.
11. Couzin J (2002) Protein structure: harmless proteins twist into troublemakers. Science (Wash DC) 296:28-29.
12. Deen PM, van Balkom BW, and Kamsteeg KJ (2000) Routing of the aquaporin-2 water channel in health and disease. Eur J Cell Biol 79:523-530.
13. Diaz GJ, Besecke LM, Rao M, Cybulski VA, Segreti JA, Mohning KM, Bush EN, Sauer D, Dalton C, Haviv F, et al. (1999) Improved oral activity of a novel non-peptidic GnRH antagonist, when co-administered with the protease inhibitor ritonavir, in Program and Abstracts of the 81st Annual Meeting of the Endocrine Society, San Diego, CA, Abstract P3-226.
14. Dobson CM (1999) Protein misfolding, evolution and disease. Trends Biochem Sci 24:329-332.
15. Dobson CM (2001) The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 356:133-145.
16. Ellgaard L and Helenius A (2001) ER quality control: towards an understanding at the molecular level. Curr Opin Cell Biol 13:431-437.
17. Gregersen N, Bross P, Andrese BS, Pedersen CB, Corydon TJ, and Bolund L (2001) The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders. J Inherit Metab Dis 24:189-212.
18. Hammarstrom P, Schneider F, and Kelly JW (2001) Trans-suppression of misfolding in an amyloid disease. Science (Wash DC) 293:2459-2462.
19. Hartl FU and Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science (Wash DC) 295:1852-1858.
20. Helenius A (2001) Quality control in the secretory assembly line. Phil Trans R Soc Lond 356:147-150.
21. Huckle WR and Conn PM (1987) The use of lithium ion in measurement of stimulated pituitary inositol phospholipid turnover. Methods Enzymol 141:149-155.
22. Janovick JA, Maya-Núñez G, and Conn PM (2002) Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel diseased etiology and therapeutic target. J Clin Endocrinol Metab 87:3255-3262.
23. Kopito RR and Ron D (2000) Conformational disease. Nat Cell Biol 2:E207-209.
24. Leaños-Miranda A, Janovick J, and Conn PM (2002) Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in GnRHR-mediated hypogonadotropic hypogonadism. J Clin Endo Metab 87:4825-4828.
25. Luque I, Leavitt SA, and Freire E (2002) The linkage between protein folding and functional cooperativity: two sides of the same coin? Annu Rev Biophys Biomol Struct 31:235-256.
26. Maya-Núñez G, Janovick J, and Conn PM (2000) Combined modification of intracellular and extracellular loci on human gonadotropin-releasing hormone receptor provides a mechanism for enhanced expression. Endocrine 13:401-409.
27. Maya-Núñez G, Janovick J, Ulloa-Aguirre A, Söderlund D, Conn PM, and Méndez JP (2002) Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E90K) GnRH receptor function by a deletion at a distant site. J Clin Endocrinol Metab 87:2144-2149.
28. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG, and Bouvier M (2000) Pharmacologicalchaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Investig 105:887-895.
29. Petäjä-Repo UE, Hogue M, Laperriere A, Bhalla S, Walker P, and Bouvier M (2001) Newly synthesized human delta opioid receptors are retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated and degraded by the proteasome. J Biol Chem 276:4416-4423.
30. Radford SE and Dobson CM (1999) From computer simulations to human disease: emerging themes in protein folding. Cell 97:291-298.
31. Sanders CR and Nagy JK (2000) Misfolding of membrane proteins in health and disease: the lady or the tiger? Curr Opin Struct Biol 10:438-442.
32. Sherman MY and Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29:15-32.